21/10 2025
The selection of appropriate raw materials for medical bandages is a critical aspect of ensuring patient safety and treatment efficacy. With the medical device industry increasingly focused on biocompatibility, regulatory compliance, and performance optimization, understanding the standards that govern material selection has never been more important. This comprehensive guide examines the key criteria, regulatory frameworks, and practical considerations that manufacturers must address when selecting raw materials for medical bandages.
The ISO 10993 series represents the international standard for evaluating the biocompatibility of medical devices, including bandages and wound dressings. According to the International Organization for Standardization (ISO), biocompatibility is defined as “the ability of a medical device or material to perform with an appropriate host response in a specific application.”
ISO 10993-1:2018, which focuses on evaluation and testing within a risk management process, serves as the cornerstone for material assessment. This standard emphasizes a risk-based approach that goes beyond simple categorization, requiring manufacturers to evaluate biocompatibility throughout the entire lifecycle of the device. The standard classifies medical devices according to the nature and duration of their interaction with the human body, with contact categories ranging from limited exposure (less than 24 hours) to permanent contact (more than 30 days).
The U.S. Food and Drug Administration (FDA) has issued specific guidance on the use of ISO 10993-1 to support premarket applications for medical devices. The FDA’s guidance document emphasizes risk-based approaches to determine if biocompatibility testing is needed and provides recommendations for chemical assessment. For wound dressings, the FDA recommends evaluating biocompatibility as described in their guidance for limited contact devices contacting compromised skin.
It is important to note that there are no FDA-approved or EU Medical Device Regulation (MDR) approved materials per se. As industry experts explain, standards apply to the devices themselves rather than individual materials. If a device as a whole meets regulatory requirements, the material is considered suitable for that specific application. This means that material selection must be evaluated in the context of the final device’s intended use, contact duration, and manufacturing processes.
Cotton remains the most widely used material for medical bandages, particularly for absorbent gauze products. Medical absorbent cotton must meet stringent quality standards:
Physical Properties:
Yarn Specifications: Cotton yarns used in medical gauze typically range from 21’s to 40’s count, with mesh configurations varying from 19×15 to 30×20 threads per square inch. These specifications directly impact the bandage’s absorbency, strength, and conformability.
Structural Considerations: Medical gauze can be produced through woven or nonwoven manufacturing processes. Woven gauze structures provide controlled wetting and fluid absorbency, while nonwoven structures offer advantages in terms of fiber shedding reduction and manufacturing efficiency.
Recent research has demonstrated the potential for enhanced cotton bandage materials. A collaborative study by the USDA Agricultural Research Service (ARS) and H&H Medical Corporation developed a revolutionary gauze made from raw, unbleached cotton fiber. By preserving the lipids, waxes, and pectin in the fiber’s outer cuticle rather than subjecting it to traditional scouring and bleaching processes, researchers discovered that the material stimulated the body’s production of blood-clotting agents. Studies conducted with Virginia Commonwealth University confirmed that this nonwoven cotton gauze triggered blood clotting more quickly than bleached cotton gauzes and shed fewer fibers. The resulting product, TACgauze, demonstrates how material processing methods can significantly impact clinical performance.
Beyond traditional cotton, modern medical bandages incorporate various synthetic materials:
Polyester and Polypropylene: These materials are used in elastic bandages and specialized wound care products, offering enhanced strength and durability. Polyester structures are particularly suitable for applications requiring higher tensile strength.
Viscose and Rayon: These regenerated cellulose fibers provide excellent absorbency and are often used in the direct-contact layer of wound dressings. Their soft, non-adherent properties make them suitable for minimizing trauma during dressing changes.
Spandex and Elastic Fibers: Incorporated into compression bandages to provide controlled pressure and support. Elastic bandages typically contain 56% polyamide and 44% cotton for optimal stretch and recovery properties.
Advanced Materials: Newer materials include polylactic acid (PLA) fibers derived from natural sources that are completely biodegradable, addressing environmental concerns while maintaining clinical performance.
According to ISO 10993-1, medical bandages that contact compromised skin require specific biocompatibility endpoints to be evaluated:
Cytotoxicity Testing (ISO 10993-5): Assesses the potential for materials to cause cell death or inhibit cell growth through in vitro testing methods.
Sensitization Testing (ISO 10993-10): Evaluates the potential for materials to cause allergic reactions through repeated exposure studies.
Irritation Testing (ISO 10993-23): Determines whether materials cause localized inflammatory responses when in contact with skin or mucosal membranes.
Systemic Toxicity (ISO 10993-11): Evaluates adverse effects on organs and systems after prolonged exposure.
ISO 10993-18 focuses on the chemical characterization of medical device materials, which is an essential first step in biocompatibility assessment. Manufacturers must identify and quantify chemical constituents that may be released from the device, including:
The selected raw materials must be compatible with the intended sterilization method:
Medical absorbent cotton and gauze materials must undergo rigorous quality control testing:
While ISO 13485:2016 (Medical devices — Quality management systems) does not specifically require raw material suppliers to hold ISO 13485 certification, manufacturers must establish robust supplier evaluation and monitoring processes. The standard requires a risk-based approach to supplier control, considering:
Manufacturers must maintain complete traceability of raw materials, including:
The FDA classifies wound dressings based on their composition and intended use. Simple gauze dressings made from cotton cellulose without antimicrobial agents or animal-derived materials are typically classified as Class I or Class II devices. However, dressings containing antimicrobials or other chemicals require additional evaluation and may need 510(k) premarket notification.
According to FDA guidance, nonresorbable gauze/sponges for external use consist of strips, pieces, or pads made from open woven or nonwoven mesh cotton cellulose or simple chemical derivatives of cellulose. These devices must be sterile when indicated and must not contain added drugs or biologics unless specifically classified as combination products.
Medical bandages are categorized based on their contact with the body:
The duration of contact further influences testing requirements:
Modern material selection increasingly considers environmental impact. Natural fibers like cotton, alginate, and chitosan offer inherent biodegradability. Emerging materials such as PLA fibers combine biodegradability with acceptable clinical performance, addressing healthcare waste concerns.
Material selection should consider:
When selecting raw materials for medical bandages, manufacturers should evaluate:
Clinical Requirements:
Regulatory Compliance:
Manufacturing Feasibility:
Performance Validation:
Comprehensive documentation must include:
The development of modern gauze bandage standards illustrates the evolution of material requirements. Traditional gauze bandages utilized bleached cotton with standardized mesh counts (typically 24×20 or 19×15). However, research has shown that processing methods significantly impact clinical performance.
The TACgauze development demonstrates this principle. By retaining natural compounds in the cotton fiber’s cuticle, researchers achieved superior hemostatic properties while reducing fiber shedding—a common complication with traditional gauze. This innovation highlights the importance of understanding not just what materials to use, but how processing affects their clinical performance.
Emerging technologies include:
Materials designed to actively promote healing:
Selecting appropriate raw materials for medical bandages requires a comprehensive understanding of regulatory standards, biocompatibility requirements, clinical performance criteria, and manufacturing considerations. The ISO 10993 series provides the fundamental framework for biocompatibility assessment, while FDA guidance and international regulations establish specific requirements for market approval.
Successful material selection depends on integrating multiple factors: ensuring patient safety through rigorous biocompatibility testing, meeting regulatory compliance requirements, achieving desired clinical performance, and maintaining manufacturing feasibility. As the field continues to evolve with new materials and technologies, manufacturers must remain vigilant in staying current with standards updates and emerging best practices.
The ultimate goal remains unchanged: providing safe, effective medical bandages that promote healing while minimizing risks to patients. By adhering to established standards and embracing innovation responsibly, manufacturers can contribute to improved patient outcomes and advancing the state of wound care.
This article is intended for informational purposes and should not replace consultation with regulatory experts and testing laboratories for specific product development decisions.
From manufacturing specifications to compliance standards, we support your procurement journey.
Kingphar Medical Group New’s 06/10 2026 No results See all results Table of Contents Incoming Quality Inspection (IQI) for Medical Consumables: Complete Guide Procurement Quality ·
Kingphar Medical Group New’s 06/10 2026 No results See all results Table of Contents Incoterms for Medical Supplies: FOB vs CIF vs DDP Explained (2026) Procurement
Kingphar Medical Group New’s 21/9 2026 No results See all results Table of Contents Inventory Management · Procurement Guide Medical ConsumablesShelf Life & ExpiryManagement Guide Shelf
Kingphar Medical Group New’s 31/8 2026 No results See all results Table of Contents Procurement Guide · Tender Writing How to Write Medical ConsumableTender SpecificationsThat Win
Kingphar Medical Group New’s 18/8 2026 No results See all results Table of Contents Procurement Guide · Import & Customs Medical ConsumablesImport Documentation:The Complete Checklist A
Kingphar Medical Group New’s 7/8 2026 No results See all results Table of Contents Procurement Guide · Import & Customs Medical Consumables HS Codes:Classification & ImportDuty
Cooperation, innovation and win-win
Don’t miss our future updates! Get Subscribed Today!
